National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
NMPA Approval | 10/03/2026 | By News Bureau
Mabwell Gets NMPA Approval for Clinical Trial of Nectin-4 Targeting ADC in TNBC
Mabwell has announced that its novel Nectin-4 targeting ADC has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC).
NMPA Approval | 16/07/2024 | By Aishwarya | 256
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy